



Supplemental Figure 1: Transitioning From Ruxolitinib to Mometlotinib




Supplemental Figure 1: *including 22/56 with Fedratinib

Supplemental Figure 2: Palpable spleen (a) and total symptoms score (b) and transfusion rate (c) variations at 3 months



Supplemental Figure 3: TSS, Total Symptoms Score

Supplemental Figure 3: Baseline predictors of IWG-MRT spleen response at 3 and/or 6 months



Supplemental Figure 3: SMF, secondary myelofibrosis; PMF, primary myelofibrosis; BCM, below costal margin; DIPSS, Dynamic International Prognostic Scoring System; Int, Intermediate; RUX, ruxolitinib; MMB, momelotinib; SR50, spleen length reduction of at least 50%.

Supplemental Figure 4: Progression-Free Survival by combined improvement in anemia and spleen size at 3 months (a) and 6 months (b)

